Lexeo Therapeutics, Inc. (LXEO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.90-10.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LXEO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
LXEO — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-09-29
Unregistered Sales of Equity Securities. The information set forth in
Why it matters: The pivotal LX2006 study needs steady enrollment to reach its planned 2027 data readout.
Supportive ifCompany updates show enrollment is advancing. Topline data remains on track for the second half of 2027.
Worry ifCompany updates report slow enrollment or push the topline readout past the second half of 2027.
Why it matters: Lexeo is loss-making and plans to fund its trials and one acquired program with its current cash. A shorter runway could force a change in plans.
Worry ifA later company update says cash and investments will fund operations into 2028. Spending remains within the stated plan.
Less concerning ifA company update cuts runway to before 2028 or reports a need to raise funds sooner.
Why it matters: The study tests whether LX2006 can lower heart mass in treated patients. This result is key to the planned approval path.
Watch forAt six months, the study reports an LVMI effect of 15% or more versus untreated controls.
Also watch forAt six months, the study reports an LVMI effect below 15% versus untreated controls.
Why it matters: Lexeo plans to pick an acquired FA program for clinical work. The choice will show where it puts its limited research funds.
Watch forBy early 2027, Lexeo names a Mantle program to advance and confirms an IND filing plan for 2027.
Also watch forThe update slips past early 2027, or Lexeo names no program for clinical work.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$285 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $683 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,526 loss on $10,000 · 75.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA plan can clarify what evidence Lexeo needs beyond the pivotal study for full approval.
Watch forLexeo reports an agreed plan with the FDA. It names the evidence needed for confirmation and explains how 12-month secondary endpoints may support full approval.
Also watch forLexeo reports no agreement, or says the FDA wants more evidence or a changed trial plan.